Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study-Reference-Cited by-同舟云学术

Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study

Published:2022-12-17 Issue: Volume:12 Page:
ISSN:2047-2978
Container-title:Journal of Global Health
language:
Short-container-title:J Glob Health

Author:

Cai Lele¹,Tao Tiantian¹,Li Hongtao¹,Zhang Zhuolin¹,Zhang Lingli¹,Li Xin¹²³

Affiliation:

1. Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, China

2. Department of Health Policy, School of Health Policy and Management, Nanjing Medical University, Nanjing, China

3. Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China

Publisher

International Society of Global Health

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference61 articles.

1. World Health Organization. Cancer. 2022. Available: https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed: 4 Jul 2022.

2. World Health Organization. Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020-IARC. 2020. Available: https://www.iarc.who.int/fr/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020/. Accessed: 4 Jul 2022.

3. Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter, cross-sectional survey.;Huang;Chin J Cancer,2017

4. Financial hardship in Chinese cancer survivors.;Su;Cancer,2020

5. Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries.;Shih;J Clin Oncol,2017

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of national reimbursement anticancer medications availability in China: based on a medical institution perspective;BMC Public Health;2024-08-21

2. Access to essential and innovative anti-cancer medicines: a longitudinal study in Nanjing, China;BMC Health Services Research;2024-07-11

3. Comparison Between Sotorasib with Docetaxel for the Treatment of Chinese Patients with Previously Treated NSCLC with KRASG12C Mutation: A Cost-Effectiveness Analysis to Inform Drug Pricing;Advances in Therapy;2024-06-18

4. Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis;International Journal for Equity in Health;2024-06-05

5. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data;BMC Public Health;2024-05-14